GlassScriptPhysician profile
Benjamin Spencer
NPI 1316588858
$1,432.53
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,305 · 2024: $127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,433.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,432.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $171.96 | 2023 | |
| Biogen, INC. | $157.16 | 2023 | Vumerity, Skyclarys |
| Novartis Pharmaceuticals Corporation | $148.45 | 2023 | |
| Livanova USA, INC. | $141.44 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
| Ucb, INC. | $89.50 | 2023 | Briviact |
| Alnylam Pharmaceuticals INC. | $78.46 | 2023 | Amvuttra |
| Sk Life Science, INC. | $76.88 | 2023-2024 | |
| Alexion Pharmaceuticals, INC. | $73.16 | 2023 | Soliris, Ultomiris |
| Teva Pharmaceuticals USA, INC. | $72.40 | 2023 | Austedo Xr |
| Jazz Pharmaceuticals INC. | $50.28 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $45.06 | 2023 | Rexulti, Nuedexta |
| Neurocrine Biosciences, INC. | $43.18 | 2023-2024 | Ingrezza, Ongentys |
| Acadia Pharmaceuticals INC | $40.40 | 2023-2024 | Nuplazid |
| Harmony Biosciences LLC | $34.31 | 2023 | Wakix |
| Amgen INC. | $29.82 | 2024 | Prolia, Evenity |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz Pharmaceuticals, LLC | $27.74 | 2023 | Xeomin |
| Bioventus LLC | $24.76 | 2024 | Exogen Ultrasound Bone Healing System |
| Lundbeck LLC | $22.29 | 2023 | Vyepti |
| Ani Pharmaceuticals, INC. | $20.50 | 2023 | Purified Cortrophin Gel |
| Amneal Pharmaceuticals LLC | $17.64 | 2023 | Rytary |
| Emd Serono, INC. | $17.22 | 2023 | Mavenclad |
| Genentech USA, INC. | $17.04 | 2023 | Ocrevus |
| Tg Therapeutics, INC. | $16.69 | 2023 | |
| Xeris Pharmaceuticals, INC. | $16.19 | 2023 | Keveyis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Spencer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.